董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nancy K. Bryan | 女 | Independent Director | 67 | 12.50万美元 | 未持股 | 2025-12-16 |
| David I. Chemerow | 男 | Independent Director | 74 | 未披露 | 未持股 | 2025-12-16 |
| Thomas K. Equels | 男 | Director,Executive Vice Chairman, Chief Executive Officer and President | 72 | 108.97万美元 | 未持股 | 2025-12-16 |
| Ted D. Kellner | 男 | Independent Director | 79 | 未披露 | 未持股 | 2025-12-16 |
| William M. Mitchell | 男 | Independent Director and Chair | 91 | 29.46万美元 | 未持股 | 2025-12-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Dickey, IV | 男 | Chief Financial Officer | 69 | 4.95万美元 | 未持股 | 2025-12-16 |
| Thomas K. Equels | 男 | Director,Executive Vice Chairman, Chief Executive Officer and President | 72 | 108.97万美元 | 未持股 | 2025-12-16 |
| Peter W. Rodino, III | 男 | Chief Operating Officer,Secretary and General Counsel | 73 | 52.13万美元 | 未持股 | 2025-12-16 |
董事简历
中英对照 | 中文 | 英文- Nancy K. Bryan
-
Nancy K. Bryan是一位在生命科学工业领域拥有超过35年经验的知名领导者。她曾在执行领导团队任职，并在生物制药公司的成功中发挥了关键作用，包括市场营销、销售、biness开发、融资和沟通。从2013年到2023年，布赖恩女士担任支持佛罗里达州生命科学发展的协会BioFlorida Inc.的总裁兼首席执行官。在加入BioFlorida之前，Bryan女士的职业生涯始于主要制药公司，包括默沙东、葛兰素史克和拜耳制药。随后，她在特种制药和较小的、创办了生物技术公司的多个行政领导职位上任职，包括Elon Pharmaceuticals、Indev Pharmaceuticals和NPS生物制药。在她的整个职业生涯中，Bryan女士帮助开发、推出和商业化了许多产品，包括blockbters（Zantac、Levitra）、major biologics（Tysabri）和罕见疾病孤儿药（Valstar治疗膀胱癌、Supprelin LA治疗中枢性早熟青春期），并帮助建立了广泛的治疗领域的特许经营权，包括肿瘤学、抗感染药、GI和自身免疫（MS、CD）。
Nancy K. Bryan is an established leader with more than 35 years of experience in the life sciences indtry. She has served on executive leadership teams and played key roles in biopharmaceutical companies' successes, including marketing, sales, biness development, financing, and communications. From 2013 to 2023, Ms. Bryan served as President and CEO of BioFlorida Inc., an association supporting the advancement of life sciences in Florida. Prior to joining BioFlorida, Ms. Bryan began her career with major pharmaceutical companies including Merck, GlaxoSmithKline and Bayer Pharmaceuticals. She then nt on to serve in a number of executive leadership positions in specialty pharmaceuticals and smaller, start up biotech companies, including Elon Pharmaceuticals, Indev Pharmaceuticals and NPS Pharmaceuticals. Throughout her career, Ms. Bryan helped develop, launch, and commercialize many products including blockbters (Zantac, Levitra), major biologics (Tysabri) and orphan drugs for rare diseases (Valstar for bladder cancer, Supprelin LA for central precocio puberty), and helped establish franchises in a wide variety of therapeutic areas, including Oncology, Anti infectives, GI and Autoimmune (MS, CD). - Nancy K. Bryan是一位在生命科学工业领域拥有超过35年经验的知名领导者。她曾在执行领导团队任职，并在生物制药公司的成功中发挥了关键作用，包括市场营销、销售、biness开发、融资和沟通。从2013年到2023年，布赖恩女士担任支持佛罗里达州生命科学发展的协会BioFlorida Inc.的总裁兼首席执行官。在加入BioFlorida之前，Bryan女士的职业生涯始于主要制药公司，包括默沙东、葛兰素史克和拜耳制药。随后，她在特种制药和较小的、创办了生物技术公司的多个行政领导职位上任职，包括Elon Pharmaceuticals、Indev Pharmaceuticals和NPS生物制药。在她的整个职业生涯中，Bryan女士帮助开发、推出和商业化了许多产品，包括blockbters（Zantac、Levitra）、major biologics（Tysabri）和罕见疾病孤儿药（Valstar治疗膀胱癌、Supprelin LA治疗中枢性早熟青春期），并帮助建立了广泛的治疗领域的特许经营权，包括肿瘤学、抗感染药、GI和自身免疫（MS、CD）。
- Nancy K. Bryan is an established leader with more than 35 years of experience in the life sciences indtry. She has served on executive leadership teams and played key roles in biopharmaceutical companies' successes, including marketing, sales, biness development, financing, and communications. From 2013 to 2023, Ms. Bryan served as President and CEO of BioFlorida Inc., an association supporting the advancement of life sciences in Florida. Prior to joining BioFlorida, Ms. Bryan began her career with major pharmaceutical companies including Merck, GlaxoSmithKline and Bayer Pharmaceuticals. She then nt on to serve in a number of executive leadership positions in specialty pharmaceuticals and smaller, start up biotech companies, including Elon Pharmaceuticals, Indev Pharmaceuticals and NPS Pharmaceuticals. Throughout her career, Ms. Bryan helped develop, launch, and commercialize many products including blockbters (Zantac, Levitra), major biologics (Tysabri) and orphan drugs for rare diseases (Valstar for bladder cancer, Supprelin LA for central precocio puberty), and helped establish franchises in a wide variety of therapeutic areas, including Oncology, Anti infectives, GI and Autoimmune (MS, CD).
- David I. Chemerow
-
David I. Chemerow于2025年2月获委任为董事。2016年8月至2017年9月，Chemerow先生担任康姆斯克，Inc.的首席财务官和财务主管，2016年1月至2016年8月，Chemerow先生担任TERM0，Inc.的首席营收官。Comscore, Inc. Chemerow先生自2009年10月起担任Rentrak Corporation的首席运营官和首席财务官，直至Rentrak Corporation于2016年1月并入康姆斯克，Inc.。在2009年之前，Chemerow先生曾在多家公司担任首席财务官或首席运营官。Chemerow先生于2018年至2024年期间担任纳斯达克和OTC公司RiceBran Technologies，Inc.的董事会成员，并担任审计委员会主席以及薪酬、提名和治理委员会成员。Chemerow Previoly先生曾担任Playboy Enterprises，Inc.董事会的非执行董事长，并且是体育用品零售商Dunham’s Athleisure Corporation的董事会成员。Chemerow先生还是户外广告公司Huntington Outdoor，LLC顾问委员会的成员。Chemerow先生担任Pilot Hill农场协会董事会副主席。Chemerow先生毕业于达特茅斯学院，拥有Amos Tuck学校的Biness Administration硕士学位。
David I. Chemerow was appointed as a Director in February 2025. From Augt 2016 to September 2017, Mr. Chemerow served as the chief financial officer and treasurer of Comscore, Inc. and from January 2016 to Augt 2016, Mr. Chemerow served as the chief revenue officer of Comscore, Inc. Mr. Chemerow served as the chief operating officer and chief financial officer of Rentrak Corporation from October 2009 until Rentrak Corporation was merged into Comscore, Inc. in January 2016. Prior to 2009, Mr. Chemerow served as chief financial officer or chief operating officer of several companies. Mr. Chemerow was a member of the board of directors of RiceBran Technologies, Inc., a Nasdaq and OTC company, from 2018 to 2024 and served as the chair of the audit committee and a member of the compensation and nominating and governance committees. Mr. Chemerow previoly served as the non executive chairman of the board of Playboy Enterprises, Inc. and is a member of the board of directors of Dunham's Athleisure Corporation, a sporting goods retailer. Mr. Chemerow is also a member of the advisory board of Huntington Outdoor, LLC, an outdoor advertising company. Mr. Chemerow serves as vice president of the board of the Pilot Hill Farm Association. Mr. Chemerow is a graduate of Dartmouth College and holds a Master of Biness Administration degree from The Amos Tuck School. - David I. Chemerow于2025年2月获委任为董事。2016年8月至2017年9月，Chemerow先生担任康姆斯克，Inc.的首席财务官和财务主管，2016年1月至2016年8月，Chemerow先生担任TERM0，Inc.的首席营收官。Comscore, Inc. Chemerow先生自2009年10月起担任Rentrak Corporation的首席运营官和首席财务官，直至Rentrak Corporation于2016年1月并入康姆斯克，Inc.。在2009年之前，Chemerow先生曾在多家公司担任首席财务官或首席运营官。Chemerow先生于2018年至2024年期间担任纳斯达克和OTC公司RiceBran Technologies，Inc.的董事会成员，并担任审计委员会主席以及薪酬、提名和治理委员会成员。Chemerow Previoly先生曾担任Playboy Enterprises，Inc.董事会的非执行董事长，并且是体育用品零售商Dunham’s Athleisure Corporation的董事会成员。Chemerow先生还是户外广告公司Huntington Outdoor，LLC顾问委员会的成员。Chemerow先生担任Pilot Hill农场协会董事会副主席。Chemerow先生毕业于达特茅斯学院，拥有Amos Tuck学校的Biness Administration硕士学位。
- David I. Chemerow was appointed as a Director in February 2025. From Augt 2016 to September 2017, Mr. Chemerow served as the chief financial officer and treasurer of Comscore, Inc. and from January 2016 to Augt 2016, Mr. Chemerow served as the chief revenue officer of Comscore, Inc. Mr. Chemerow served as the chief operating officer and chief financial officer of Rentrak Corporation from October 2009 until Rentrak Corporation was merged into Comscore, Inc. in January 2016. Prior to 2009, Mr. Chemerow served as chief financial officer or chief operating officer of several companies. Mr. Chemerow was a member of the board of directors of RiceBran Technologies, Inc., a Nasdaq and OTC company, from 2018 to 2024 and served as the chair of the audit committee and a member of the compensation and nominating and governance committees. Mr. Chemerow previoly served as the non executive chairman of the board of Playboy Enterprises, Inc. and is a member of the board of directors of Dunham's Athleisure Corporation, a sporting goods retailer. Mr. Chemerow is also a member of the advisory board of Huntington Outdoor, LLC, an outdoor advertising company. Mr. Chemerow serves as vice president of the board of the Pilot Hill Farm Association. Mr. Chemerow is a graduate of Dartmouth College and holds a Master of Biness Administration degree from The Amos Tuck School.
- Thomas K. Equels
-
Thomas K. Equels，自2008年起担任公司董事并担任公司执行副主席首席执行官（自2016年起）和总裁（自2015年起）。Equels先生是总部位于佛罗里达州迈阿密的专注于诉讼的Equels律师事务所的所有者和前任总裁兼董事总经理。四分之一个多世纪以来，Equels先生代表国家和州政府以及银行、保险、航空、制药和建筑行业的公司。Equels先生以很高的荣誉获得了佛罗里达州立大学的法学博士学位。他以优异成绩获得了特洛伊大学的理学学士学位，还获得了特洛伊大学的理学硕士学位。Equels先生的职业生涯始于一名军事飞行员。他曾在越南服役，获颁两枚杰出飞行十字勋章、铜星勋章、紫心勋章、十五枚空中勋章。2012年，他被教宗本笃十六世封为爵士。
Thomas K. Equels has been a Director and serves as the Company's Executive Vice Chairman since 2008 Chief Executive Officer (since 2016) and President (since 2015). Mr. Equels was the owner of and former President and Managing Director of the Equels Law Firm headquartered in Miami, Florida that focused on litigation. For over a quarter century, Mr. Equels represented national and state governments as well as companies in the banking, insurance, aviation, pharmaceutical and construction industries. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He received his Bachelor of Science, summa cum laude, from Troy University and also obtained his Masters' of Science Degree from Troy University. Mr. Equels began his professional career as a military pilot. He served in Vietnam and was awarded two Distinguished Flying Crosses, the Bronze Star, the Purple Heart, and fifteen Air Medals. In 2012 he was Knighted by Pope Benedict. - Thomas K. Equels，自2008年起担任公司董事并担任公司执行副主席首席执行官（自2016年起）和总裁（自2015年起）。Equels先生是总部位于佛罗里达州迈阿密的专注于诉讼的Equels律师事务所的所有者和前任总裁兼董事总经理。四分之一个多世纪以来，Equels先生代表国家和州政府以及银行、保险、航空、制药和建筑行业的公司。Equels先生以很高的荣誉获得了佛罗里达州立大学的法学博士学位。他以优异成绩获得了特洛伊大学的理学学士学位，还获得了特洛伊大学的理学硕士学位。Equels先生的职业生涯始于一名军事飞行员。他曾在越南服役，获颁两枚杰出飞行十字勋章、铜星勋章、紫心勋章、十五枚空中勋章。2012年，他被教宗本笃十六世封为爵士。
- Thomas K. Equels has been a Director and serves as the Company's Executive Vice Chairman since 2008 Chief Executive Officer (since 2016) and President (since 2015). Mr. Equels was the owner of and former President and Managing Director of the Equels Law Firm headquartered in Miami, Florida that focused on litigation. For over a quarter century, Mr. Equels represented national and state governments as well as companies in the banking, insurance, aviation, pharmaceutical and construction industries. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He received his Bachelor of Science, summa cum laude, from Troy University and also obtained his Masters' of Science Degree from Troy University. Mr. Equels began his professional career as a military pilot. He served in Vietnam and was awarded two Distinguished Flying Crosses, the Bronze Star, the Purple Heart, and fifteen Air Medals. In 2012 he was Knighted by Pope Benedict.
- Ted D. Kellner
-
Ted D. Kellner，担任Fiduciary Management公司（投资管理公司）的主席兼首席执行官（1980年以来），也担任American Family Mutual Insurance Company和Kelben Foundation公司、Metavante Technologies公司（一个上市公司，为金融服务公司提供银行和支付技术）的董事（从2007年到2009年），还一直担任公司的董事（2000年4月以来）。
Ted D. Kellner was elected as a Director of the Company in December 2024. Mr. Kellner is a Chartered Financial Analyst with 50 years of investment experience and currently manages his personal and family investments after retiring in 2017 from his career as a portfolio manager at Fiduciary Management, Inc., an investment management firm that he founded in 1980. Fiduciary Management, Inc. currently manages approximately $15 billion in assets, pension and profit sharing trts, Taft Hartley and public funds, endowments and personal trts throughout the United States. He is also the Chairman of Fiduciary Real Estate Development Inc., a biness founded by Mr. Kellner in 1984 that owns and manages over $2.3 billion in multi family residential units. Mr. Kellner previoly served as a director of Metavante Technologies, Inc., a then publicly traded company that provided banking and payments technologies to financial services firms, from 2007 to 2009, and Marshall & Ilsley Corporation, a then publicly traded bank and financial holding company, from 2000 to 2011. He also served as a director of the American Family Mutual Insurance Company from 2001 to 2018, and currently serves on the board of the Kelben Foundation, a family foundation foced on education and health programs. Mr. Kellner holds a BBA in Finance, Investments, and Banking from the University of Wisconsin. - Ted D. Kellner，担任Fiduciary Management公司（投资管理公司）的主席兼首席执行官（1980年以来），也担任American Family Mutual Insurance Company和Kelben Foundation公司、Metavante Technologies公司（一个上市公司，为金融服务公司提供银行和支付技术）的董事（从2007年到2009年），还一直担任公司的董事（2000年4月以来）。
- Ted D. Kellner was elected as a Director of the Company in December 2024. Mr. Kellner is a Chartered Financial Analyst with 50 years of investment experience and currently manages his personal and family investments after retiring in 2017 from his career as a portfolio manager at Fiduciary Management, Inc., an investment management firm that he founded in 1980. Fiduciary Management, Inc. currently manages approximately $15 billion in assets, pension and profit sharing trts, Taft Hartley and public funds, endowments and personal trts throughout the United States. He is also the Chairman of Fiduciary Real Estate Development Inc., a biness founded by Mr. Kellner in 1984 that owns and manages over $2.3 billion in multi family residential units. Mr. Kellner previoly served as a director of Metavante Technologies, Inc., a then publicly traded company that provided banking and payments technologies to financial services firms, from 2007 to 2009, and Marshall & Ilsley Corporation, a then publicly traded bank and financial holding company, from 2000 to 2011. He also served as a director of the American Family Mutual Insurance Company from 2001 to 2018, and currently serves on the board of the Kelben Foundation, a family foundation foced on education and health programs. Mr. Kellner holds a BBA in Finance, Investments, and Banking from the University of Wisconsin.
- William M. Mitchell
-
William M. Mitchell，1998年7月以来一直是担任公司董事。Mitchell博士是范德比尔特大学医学院（Vanderbilt University School of Medicine）的病理学教授，是委员会的认证医生。他获得了范德比尔特大学（Vanderbilt）的医学博士学位和约翰霍普金斯大学（Johns Hopkins University）的博士学位，在那里他担内科实习医师，并获得了医学院的奖学金。他发表了超过200篇的与病毒、抗病毒药物、艾滋病毒感染的免疫反应和其他生物医学话题相关的论文、评论和摘要。他也在许多专业社会团体工作，包括美国社会病理调查学会（ American Society of Investigative Pathology）、抗病毒研究国际学会（ International Society for Antiviral Research）、美国生物化学和分子生物学学会（American Society of Biochemistry and Molecular Biology）以及美国微生物学会（American Society of Microbiology）。他还是美国医学协会的成员。他曾在多个政府审查委员会任职，其中包括美国国立卫生研究院（ National Institutes of Health）、艾滋病和相关研究小组（AIDS and Related Research Review Group）。
William M. Mitchell has served as a Professor of Pathology, Microbiology & Immunology, at Vanderbilt University School of Medicine since 1966 and is a board certified physician. Dr. Mitchell earned a M.D. from Vanderbilt and a Ph.D. from Johns Hopkins University, where he served as Hoe Officer in Internal Medicine, follod by a Fellowship at its School of Medicine. Dr. Mitchell has published over 250 papers, reviews and abstracts that relate to vires, anti viral drugs, immune responses to viral infection, detection in blood of cancer DNA (i.e., the liquid biopsy), and other biomedical topics. Dr. Mitchell has worked for and with many professional societies that have included the American Society of Investigative Pathology, the International Society for Antiviral Research, the American Society of Clinical Oncology, the American Society of Biochemistry and Molecular Biology, the American Chemical Society, and the American Society of Microbiology. Dr. Mitchell is a member of the American Medical Association. He has served on numero government review committees, among them the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health, including the initial AIDS and Related Research Review Group. Dr. Mitchell previoly served as one of the Company's directors from 1987 to 1989. - William M. Mitchell，1998年7月以来一直是担任公司董事。Mitchell博士是范德比尔特大学医学院（Vanderbilt University School of Medicine）的病理学教授，是委员会的认证医生。他获得了范德比尔特大学（Vanderbilt）的医学博士学位和约翰霍普金斯大学（Johns Hopkins University）的博士学位，在那里他担内科实习医师，并获得了医学院的奖学金。他发表了超过200篇的与病毒、抗病毒药物、艾滋病毒感染的免疫反应和其他生物医学话题相关的论文、评论和摘要。他也在许多专业社会团体工作，包括美国社会病理调查学会（ American Society of Investigative Pathology）、抗病毒研究国际学会（ International Society for Antiviral Research）、美国生物化学和分子生物学学会（American Society of Biochemistry and Molecular Biology）以及美国微生物学会（American Society of Microbiology）。他还是美国医学协会的成员。他曾在多个政府审查委员会任职，其中包括美国国立卫生研究院（ National Institutes of Health）、艾滋病和相关研究小组（AIDS and Related Research Review Group）。
- William M. Mitchell has served as a Professor of Pathology, Microbiology & Immunology, at Vanderbilt University School of Medicine since 1966 and is a board certified physician. Dr. Mitchell earned a M.D. from Vanderbilt and a Ph.D. from Johns Hopkins University, where he served as Hoe Officer in Internal Medicine, follod by a Fellowship at its School of Medicine. Dr. Mitchell has published over 250 papers, reviews and abstracts that relate to vires, anti viral drugs, immune responses to viral infection, detection in blood of cancer DNA (i.e., the liquid biopsy), and other biomedical topics. Dr. Mitchell has worked for and with many professional societies that have included the American Society of Investigative Pathology, the International Society for Antiviral Research, the American Society of Clinical Oncology, the American Society of Biochemistry and Molecular Biology, the American Chemical Society, and the American Society of Microbiology. Dr. Mitchell is a member of the American Medical Association. He has served on numero government review committees, among them the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health, including the initial AIDS and Related Research Review Group. Dr. Mitchell previoly served as one of the Company's directors from 1987 to 1989.
高管简历
中英对照 | 中文 | 英文- Robert Dickey, IV
Robert Dickey IV，自2020年3月起担任Foresite Advisors董事总经理，该公司为生命科学公司提供财务支持和战略。最近，迪基先生于2022年9月至2023年3月担任生物技术公司Enveric Biosicences，Inc.的临时首席财务官。迪基先生曾于2018年8月至2020年3月在Danforth Advisors担任董事总经理，该公司为生命科学公司提供财务和会计服务。迪基先生自2020年起担任上市生物制药公司Angiogenex，Inc.的董事会成员，自2022年起担任开发微生物衍生疗法的私有公司SFA Therapeutics的董事会成员。自2018年以来，他一直是Cell One Partners的领导团队成员，该公司是一家专注于细胞和基因治疗的战略咨询服务公司，自2021年以来，他一直是BCI生命科学公司的领导团队成员，该公司是一家附属于经纪自营商的咨询公司。迪基先生于2018年至2022年担任上市生物制药公司Emmaus Life Sciences, Inc.的董事会成员和审计委员会主席，并于2013年至2017年担任私有医疗设备公司Sanuthera公司的董事会成员。在此之前，他于2017年1月至2018年2月在纳斯达克和伦敦AIM交易所上市的抗生素公司Motif Bio Plc担任首席财务官。他还曾受雇于其他几家生物技术公司，包括2015年5月至2017年1月担任Tyme Technologies, Inc.首席财务官，2013年8月至2015年1月担任NeoStem公司首席财务官，2008年11月至2013年8月担任Hemispherx Biopharma公司高级副总裁。在此之前，迪基先生曾担任美盛集团伍德沃克公司董事总经理、雷曼兄弟高级副总裁和雷曼兄弟附属公司中间市场集团联合创始人/合伙人。迪基拥有普林斯顿大学的学士学位和宾夕法尼亚大学沃顿商学院的MBA学位。
Robert Dickey, IV has been Chief Financial Officer since April 4, 2022. Mr. Dickey was a senior vice president of the Company from 2008 until 2013. Mr. Dickey has more than 25 years of experience in C suite financial leadership for life science and medical device companies, both private and public, ranging from preclinical development to commercial operations and across a variety of disease areas and medical technologies. Mr. Dickey has served as Managing Director at Foresite Advisors since March 2020 assuming responsibility for CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A services at life science companies. Mr. Dickey serves as a member on the board of directors of AngioGenex, SFA Therapeutics and GSNO Therapeutics. Throughout his career he has demonstrated C level (CFO, COO and CEO) and Board level experience in public, private, revenue stage and development stage life sciences and medical device companies, and has played a leading role in two start ups. Earlier in his career, Mr. Dickey spent 18 years in investment banking, primarily at Lehman Brothers, with a background split beten mergers and acquisitions and capital markets transactions.- Robert Dickey IV，自2020年3月起担任Foresite Advisors董事总经理，该公司为生命科学公司提供财务支持和战略。最近，迪基先生于2022年9月至2023年3月担任生物技术公司Enveric Biosicences，Inc.的临时首席财务官。迪基先生曾于2018年8月至2020年3月在Danforth Advisors担任董事总经理，该公司为生命科学公司提供财务和会计服务。迪基先生自2020年起担任上市生物制药公司Angiogenex，Inc.的董事会成员，自2022年起担任开发微生物衍生疗法的私有公司SFA Therapeutics的董事会成员。自2018年以来，他一直是Cell One Partners的领导团队成员，该公司是一家专注于细胞和基因治疗的战略咨询服务公司，自2021年以来，他一直是BCI生命科学公司的领导团队成员，该公司是一家附属于经纪自营商的咨询公司。迪基先生于2018年至2022年担任上市生物制药公司Emmaus Life Sciences, Inc.的董事会成员和审计委员会主席，并于2013年至2017年担任私有医疗设备公司Sanuthera公司的董事会成员。在此之前，他于2017年1月至2018年2月在纳斯达克和伦敦AIM交易所上市的抗生素公司Motif Bio Plc担任首席财务官。他还曾受雇于其他几家生物技术公司，包括2015年5月至2017年1月担任Tyme Technologies, Inc.首席财务官，2013年8月至2015年1月担任NeoStem公司首席财务官，2008年11月至2013年8月担任Hemispherx Biopharma公司高级副总裁。在此之前，迪基先生曾担任美盛集团伍德沃克公司董事总经理、雷曼兄弟高级副总裁和雷曼兄弟附属公司中间市场集团联合创始人/合伙人。迪基拥有普林斯顿大学的学士学位和宾夕法尼亚大学沃顿商学院的MBA学位。
- Robert Dickey, IV has been Chief Financial Officer since April 4, 2022. Mr. Dickey was a senior vice president of the Company from 2008 until 2013. Mr. Dickey has more than 25 years of experience in C suite financial leadership for life science and medical device companies, both private and public, ranging from preclinical development to commercial operations and across a variety of disease areas and medical technologies. Mr. Dickey has served as Managing Director at Foresite Advisors since March 2020 assuming responsibility for CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A services at life science companies. Mr. Dickey serves as a member on the board of directors of AngioGenex, SFA Therapeutics and GSNO Therapeutics. Throughout his career he has demonstrated C level (CFO, COO and CEO) and Board level experience in public, private, revenue stage and development stage life sciences and medical device companies, and has played a leading role in two start ups. Earlier in his career, Mr. Dickey spent 18 years in investment banking, primarily at Lehman Brothers, with a background split beten mergers and acquisitions and capital markets transactions.
- Thomas K. Equels
Thomas K. Equels，自2008年起担任公司董事并担任公司执行副主席首席执行官（自2016年起）和总裁（自2015年起）。Equels先生是总部位于佛罗里达州迈阿密的专注于诉讼的Equels律师事务所的所有者和前任总裁兼董事总经理。四分之一个多世纪以来，Equels先生代表国家和州政府以及银行、保险、航空、制药和建筑行业的公司。Equels先生以很高的荣誉获得了佛罗里达州立大学的法学博士学位。他以优异成绩获得了特洛伊大学的理学学士学位，还获得了特洛伊大学的理学硕士学位。Equels先生的职业生涯始于一名军事飞行员。他曾在越南服役，获颁两枚杰出飞行十字勋章、铜星勋章、紫心勋章、十五枚空中勋章。2012年，他被教宗本笃十六世封为爵士。
Thomas K. Equels has been a Director and serves as the Company's Executive Vice Chairman since 2008 Chief Executive Officer (since 2016) and President (since 2015). Mr. Equels was the owner of and former President and Managing Director of the Equels Law Firm headquartered in Miami, Florida that focused on litigation. For over a quarter century, Mr. Equels represented national and state governments as well as companies in the banking, insurance, aviation, pharmaceutical and construction industries. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He received his Bachelor of Science, summa cum laude, from Troy University and also obtained his Masters' of Science Degree from Troy University. Mr. Equels began his professional career as a military pilot. He served in Vietnam and was awarded two Distinguished Flying Crosses, the Bronze Star, the Purple Heart, and fifteen Air Medals. In 2012 he was Knighted by Pope Benedict.- Thomas K. Equels，自2008年起担任公司董事并担任公司执行副主席首席执行官（自2016年起）和总裁（自2015年起）。Equels先生是总部位于佛罗里达州迈阿密的专注于诉讼的Equels律师事务所的所有者和前任总裁兼董事总经理。四分之一个多世纪以来，Equels先生代表国家和州政府以及银行、保险、航空、制药和建筑行业的公司。Equels先生以很高的荣誉获得了佛罗里达州立大学的法学博士学位。他以优异成绩获得了特洛伊大学的理学学士学位，还获得了特洛伊大学的理学硕士学位。Equels先生的职业生涯始于一名军事飞行员。他曾在越南服役，获颁两枚杰出飞行十字勋章、铜星勋章、紫心勋章、十五枚空中勋章。2012年，他被教宗本笃十六世封为爵士。
- Thomas K. Equels has been a Director and serves as the Company's Executive Vice Chairman since 2008 Chief Executive Officer (since 2016) and President (since 2015). Mr. Equels was the owner of and former President and Managing Director of the Equels Law Firm headquartered in Miami, Florida that focused on litigation. For over a quarter century, Mr. Equels represented national and state governments as well as companies in the banking, insurance, aviation, pharmaceutical and construction industries. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He received his Bachelor of Science, summa cum laude, from Troy University and also obtained his Masters' of Science Degree from Troy University. Mr. Equels began his professional career as a military pilot. He served in Vietnam and was awarded two Distinguished Flying Crosses, the Bronze Star, the Purple Heart, and fifteen Air Medals. In 2012 he was Knighted by Pope Benedict.
- Peter W. Rodino, III
Peter W. Rodino, III ，在2013年7月被任命为公司董事，目前担任董事会主席、审计委员会的财务专家、薪酬委员会成员以及董事会治理和提名委员会成员。Richard c . Piani先生因健康原因辞职，于是公司任命Rodino先生任职。Rodino先生拥有广泛的法律、财务和行政经验。除了曾担任Rodino Consulting LLC的总裁和几家律师事务所的管理合伙人且担任了多年的执业律师之外，他还曾担任 Health Plan的董事长兼首席执行官。Health Plan是新泽西第一个主要的健康维护组织。他也有作为投资证券行业的高管和在众多Chapter 11 复杂的重组企业中作为受托人的丰富的经验。在过去的17年里，作为 Rodino Consulting的创始人兼总裁，Rodino先生为规模较小的公司提供了商业和政府关系咨询服务，专注于帮助他们开发商业计划、实施营销策略和获得投资资本。 Rodino先生是Georgetown University的工商管理学士，也是Seton Hall University的法学博士。
Peter W. Rodino, III has been a Director since July 2013. On September 30 2016 Mr. Rodino resigned as a member of our Board to permit him to serve us in a new capacity. Effective October 1 2016 we retained Mr. Rodino as our Executive Director for Governmental Relations, and as our General Counsel and, as of October 16 2019 Mr. Rodino assumed the role of Chief Operating Officer. Mr. Rodino has been our Secretary since November 2016. Mr. Rodino has broad legal, financial, and executive experience. In addition to being President of Rodino Consulting LLC and managing partner at several law firms during his many years as a practicing attorney, he served as Chairman and CEO of Crossroads Health Plan, the first major Health Maintenance Organization in New Jersey. He also has had experience as an investment executive in the securities industry and acted as trustee in numerous Chapter 11 complex corporate reorganizations. Previously, as founder and president of Rodino Consulting, Mr. Rodino provided business and government relations consulting services to smaller companies with a focus on helping them develop business plans, implement marketing strategies and acquire investment capital. Mr. Rodino holds a B.S. in Business Administration from Georgetown University and a J.D. degree from Seton Hall University.- Peter W. Rodino, III ，在2013年7月被任命为公司董事，目前担任董事会主席、审计委员会的财务专家、薪酬委员会成员以及董事会治理和提名委员会成员。Richard c . Piani先生因健康原因辞职，于是公司任命Rodino先生任职。Rodino先生拥有广泛的法律、财务和行政经验。除了曾担任Rodino Consulting LLC的总裁和几家律师事务所的管理合伙人且担任了多年的执业律师之外，他还曾担任 Health Plan的董事长兼首席执行官。Health Plan是新泽西第一个主要的健康维护组织。他也有作为投资证券行业的高管和在众多Chapter 11 复杂的重组企业中作为受托人的丰富的经验。在过去的17年里，作为 Rodino Consulting的创始人兼总裁，Rodino先生为规模较小的公司提供了商业和政府关系咨询服务，专注于帮助他们开发商业计划、实施营销策略和获得投资资本。 Rodino先生是Georgetown University的工商管理学士，也是Seton Hall University的法学博士。
- Peter W. Rodino, III has been a Director since July 2013. On September 30 2016 Mr. Rodino resigned as a member of our Board to permit him to serve us in a new capacity. Effective October 1 2016 we retained Mr. Rodino as our Executive Director for Governmental Relations, and as our General Counsel and, as of October 16 2019 Mr. Rodino assumed the role of Chief Operating Officer. Mr. Rodino has been our Secretary since November 2016. Mr. Rodino has broad legal, financial, and executive experience. In addition to being President of Rodino Consulting LLC and managing partner at several law firms during his many years as a practicing attorney, he served as Chairman and CEO of Crossroads Health Plan, the first major Health Maintenance Organization in New Jersey. He also has had experience as an investment executive in the securities industry and acted as trustee in numerous Chapter 11 complex corporate reorganizations. Previously, as founder and president of Rodino Consulting, Mr. Rodino provided business and government relations consulting services to smaller companies with a focus on helping them develop business plans, implement marketing strategies and acquire investment capital. Mr. Rodino holds a B.S. in Business Administration from Georgetown University and a J.D. degree from Seton Hall University.